Recordati S.p.A. - Recordati to co-market moxifloxacine, an important antibacterial drug, with Bayer

Press Releases

Recordati to co-market moxifloxacine, an important antibacterial drug, with Bayer

Milan, 24 October 2002

Recordati announced that it has signed a co-marketing agreement with Bayer AG for the marketing and sale in Italy of Octegra® (moxifloxacine), an anti-bacterial fluorquinolone, already marketed in Italy, indicated for the treatment of respiratory infections.

Moxifloxacine, discovered and developed by Bayer AG, is a last generation drug in its class, which is well known and established, and which recorded sales of approximately Euro 145 million in the last 12 months in Italy. There, moxifloxacine's patent protection runs until 2014.

Recordati will re-launch Octegra® in the next two months.

"The agreement with Bayer is part of our product and license acquisition plan for Italy, France and Spain, where we are present with our own sales organizations" declared Giovanni Recordati, Chairman and CEO. "The re-launch of Octegra® will follow those of Peptazol® (pantoprazole) and Lercadip® (lercanidipine) which took place at the beginning of 2002 with excellent results".

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2002 Print Page Bookmark Page
Shareholder information Recordati at a glance Key Financial Data Recordati Share Press Releases 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Calendar Analyst Coverage Contacts	Press Releases Recordati to co-market moxifloxacine, an important antibacterial drug, with Bayer Milan, 24 October 2002 Recordati announced that it has signed a co-marketing agreement with Bayer AG for the marketing and sale in Italy of Octegra® (moxifloxacine), an anti-bacterial fluorquinolone, already marketed in Italy, indicated for the treatment of respiratory infections. Moxifloxacine, discovered and developed by Bayer AG, is a last generation drug in its class, which is well known and established, and which recorded sales of approximately Euro 145 million in the last 12 months in Italy. There, moxifloxacine's patent protection runs until 2014. Recordati will re-launch Octegra® in the next two months. "The agreement with Bayer is part of our product and license acquisition plan for Italy, France and Spain, where we are present with our own sales organizations" declared Giovanni Recordati, Chairman and CEO. "The re-launch of Octegra® will follow those of Peptazol® (pantoprazole) and Lercadip® (lercanidipine) which took place at the beginning of 2002 with excellent results". Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.